---
schema_version: "secwatch.filing_event.v1"
accession: "0000937556-24-000015"
form_type: "8-K"
ticker: "MASI"
cik: "0000937556"
company_name: "MASIMO CORP"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T14:02:54.736304+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Masimo Q4 revenue $548.9M, GAAP EPS $0.63; full-year $2,048.1M; FY2024 guidance $2,045-2,165M

## Summary
- Q4 consolidated revenue $548.9M (healthcare $339.9M, non-healthcare $209.0M).
- GAAP EPS $0.63; non-GAAP EPS (updated) $1.25.
- Full-year 2023 revenue $2,048.1M; GAAP EPS $1.51; non-GAAP EPS $3.79.
- Q1 2024 guidance: revenue $476-501M; full-year 2024 revenue $2,045-2,165M.
- CEO cites record contract wins, FDA clearances, and hearables growth as momentum drivers.

## SEC filing metadata
- accession: 0000937556-24-000015
- form_type: 8-K
- ticker: MASI
- cik: 0000937556
- company_name: MASIMO CORP
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/937556/000093755624000015/0000937556-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/937556/000093755624000015/masi-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000937556-24-000015
- JSON: https://secwatch.observer/filing/0000937556-24-000015.json
- Plain text: https://secwatch.observer/filing/0000937556-24-000015.txt

## Key facts
- Earnings Releases
  MASIMO CORP reported Full-Year 2023 results: revenue $2,048.1 million, net income $81.5 million, EPS $1.51.
  - Period: Full-Year 2023
  - Revenue: $2,048.1 million
  - Net income: $81.5 million
  - EPS: $1.51
  - Result: reported results
  source text: Consolidated revenue was $2,048.1 million, consisting of healthcare revenue of $1,275.5 million and non-healthcare revenue of $772.6 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 263,000. Consolidated GAAP operating income was $136.5 million. Consolidated non-GAAP operating income (prior definition) was $269.6 million. Consolidated non-GAAP operating income (updated definition) was $313.0 million. Consolidated GAAP net income was $81.5 million, or $1.51 per diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/937556/000093755624000015/0000937556-24-000015-index.htm
- Earnings Releases
  MASIMO CORP reported Fourth Quarter 2023 results: revenue $548.9 million, net income $34.0 million, EPS $0.63.
  - Period: Fourth Quarter 2023
  - Revenue: $548.9 million
  - Net income: $34.0 million
  - EPS: $0.63
  - Result: reported results
  source text: Consolidated revenue was $548.9 million, comprised of healthcare revenue of $339.9 million and non-healthcare revenue of $209.0 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,500. Consolidated GAAP operating income was $44.1 million. Consolidated non-GAAP operating income (prior definition) was $78.6 million. Consolidated non-GAAP operating income (updated definition) was $91.7 million. Consolidated GAAP net income was $34.0 million, or $0.63 per diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/937556/000093755624000015/0000937556-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.